Niehr, F., Weichert, W., & Stenzinger, A. (2015). CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab. Journal of translational medicine, 13, . https://doi.org/10.1186/s12967-015-0456-6
Chicago-Zitierstil (17. Ausg.)Niehr, Franziska, Wilko Weichert, und Albrecht Stenzinger. "CCI-779 (Temsirolimus) Exhibits Increased Anti-tumor Activity in Low EGFR Expressing HNSCC Cell Lines and Is Effective in Cells with Acquired Resistance to Cisplatin or Cetuximab." Journal of Translational Medicine 13 (2015). https://doi.org/10.1186/s12967-015-0456-6.
MLA-Zitierstil (9. Ausg.)Niehr, Franziska, et al. "CCI-779 (Temsirolimus) Exhibits Increased Anti-tumor Activity in Low EGFR Expressing HNSCC Cell Lines and Is Effective in Cells with Acquired Resistance to Cisplatin or Cetuximab." Journal of Translational Medicine, vol. 13, 2015, https://doi.org/10.1186/s12967-015-0456-6.